Jump to content

Have we seen the top of US large caps & the FTSE100?

Recommended Posts

On a previous thread I had 2 scenarios for US large Caps and thought the Dax and Nikkei were in retrace with the FTSE possible doing either.  Now it is looking more and more like the US large Caps have fixed on one of the scenarios and turned on a Head & Shoulders formation and have  broken an ending Triangle.  Although a hard retest of the Triangle (back into the congestion zone within the Triangle) is still possible a break of this nature is a strong bearish signal.  If we get a sustained drop tomorrow then a bearish run down is on the cards and it could go for a 1000 or more points on the Dow before any serious retrace.


Looking at the Dow daily chart (S&P showing the same thing) you can see the Triangle and break, not fully clean just yet but as I said tomorrow could deliver that.  So far the breakout was stalled at the Fib 38% off the previous low (wave 4 pink) but that is being retested and RSI/Stochastic have not reached a normal turn back up point.  The EWT count shows an initial 1-2 with a second 1-2 of wave 3 completed and a strong move down to wave 3 of 3 indicated.  At some point this initial run down would complete and retrace significantly (50-62% most likely) before the real Bear gets going.


The Nasdaq has not yet broken its Triangle and is running a different EWT set up but the Russell2000 (often a front runner for the large Caps) has broken both Triangle and parallel tramlines after a double top at the Fib 88.8% (creating an effective double top on the Weekly chart too).  The FTSE100 also has not yet broken its Triangle and it looks like it has been held up while the US markets have fallen harder, possibly because of the weakness in GBP but that wont last as a positive factor in the face of a sustained US drop so the FTSE would catch up fast.  The Dax, like the Russell, has a double top on the Daily but like the FTSE has been held up, again possibly on recent Euro weakness.


On all of these charts there is strong Negative Momentum Divergence at the top or retrace turning point that does not look like its influence is over with.  All in all this has to represent a strong set up for at a minimum a decent correction and perhaps much more.



Link to comment

If it rallies it rallies, I'm stop protected and the down side potential is worth the chance of a popcorn stop out for no loss...


Any rally (on US at least) would need to break back through the Triangle line, chances are a rally will retest that line and a failure will spell a big drop.  In some ways a rally back, retest and fail is the best possible outcome as it give a great chance to get short from a low risk resistance line but equally the market could just drop away.  Interestingly there is a possible EWT1-5 count down now so a small retrace is very possible.

Link to comment

Sorry for the post spray but another thought now that we see US opening down, the next support point, if this early move continues is around the 50% fib (circa 17870), which could offer a wave 1 completion and a roughly 62% fib retrace would bring the market back to the Triangle resistance line.

Link to comment

Its funny how the minutes said last night stated that as long no external global issues occur, rates are on, only less than 12 hours later Chinese release their data, what a perfect excuse not to raise rates, funny how the markets have now conditioned themselves to this, hence why a dollar sell-of has now occurred. 

Link to comment

So at face value it looks like US large caps have retraced and retested the Triangle breakout and been repulsed.  This after a Head & Shoulders Top and neckline breakout and failed retest of that neckline.  Can't rule out another retest so will be interesting to see what happens on Monday (or possible even on the over night trading action from Asia and how that might impact the futures markets in Europe and the US).


I can't post charts at the moment (IG are working on the issue) but if I could I would post the hourly chart, which shows that the relief rally from Thursday PM to Friday PM retraced to the 62% Fib in A-B-C form on Dow, S&P, Nasdaq and FTSE100.  Only made it to the 38% on Russell2000 (now nearing a lower low) but made the 76% Fib on the Dax (**** Germans!).  Therefore it seems to me that the retest of the Triangle line coincided with an A-B-C retrace as a significant Fib level, which was enough for me to go Short and top up previous shorts from the H&S breakout.  Now the market has dropped back below key resistance points a fresh turn down on Sunday night or Monday morning and new lower lows on the move down from the top are suggestive of a larger scale wave 1 down.  Note some markets have yet to break their Triangles (FTSE and DAX and Nasdaq) so watch out for a breakout on these as a good Short opportunity (or support of course!)


The COT data is quite interesting this week with some shift to the short side on the Dow, Nasdaq and Russell with these markets still being Long weighted, particularly the Nasdaq (which has not yet fully broken it's Triangle support - on the cusp thought!).  However if you look at the E-MINI S&P500 COT data you get a very different picture.  On this market the non commercials have shifted from net 208.6k Long (661k long vs 451k short) to net -9k on the short side (502k long vs 511k short).  S&P500 is the biggest and most influential market...  At the same time there was also a shift towards net balanced on 10 year Treasury notes with a 127k move to almost parity (net 17k Long) last week.  So 10 treasury notes AND S&P heading short at the same time...  US T-bonds are also at parity while Ultras (long term) are net short by 111k but they have been at that level for a long time...


Not sure what all this really means in truth and as I said we could get another retest rally but with the E-MINIS&P500 COT all time high net Long (219k) having occurred in the last week of August 2016 just before the 10 Sept potential right hand shoulder of the H&S formation followed by a rapid COT unwinding back to parity, I'd have to say this is a bearish outlook.


Love to hear from anyone who has an alternative set up to offer. 



Link to comment
  • 2 weeks later...

We can see how markets react to good news from the EU and the risk to the beloved QE bond buying program and as well as a clear reaction to the EURO, JCB AND T-bonds as well as a rise in the yield curve. Once the Trump/Clinton saga is over, then the Italian referendum will be on the cards with the possible note of more weak data from China. Although the weak pound has really benefited the index, i am doubtful that this is going to be a forever upward pathway, due to underlying global economic factors such as persistent low inflation and low growth. 

But for now longs still seem the best trade, as they say, the trend is your friend.

Link to comment
  • 5 weeks later...
  • 2 weeks later...

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • General Statistics

    • Total Topics
    • Total Posts
    • Total Members
    • Most Online
      10/06/21 10:53

    Newest Member
    Joined 27/07/21 14:10
  • Posts

    • GlaxoSmithKline Q2 revenue is expected to show revenue growth from newer drugs partially offset by increased generic competition in older drugs. Source: Bloomberg   Shares GlaxoSmithKline Price Revenue Vaccine Earnings before interest, taxes, depreciation and amortization  Shaun Murison | Senior Market Analyst, Johannesburg | Publication date: Tuesday 27 July 2021  When is GlaxoSmithKline earnings date? The GlaxoSmithKline (GSK) earnings release date is scheduled for the 28 July 2021. The scheduled results will cover the groups second quarter and half-year earnings.   GSK results preview: What does the street expect? While GlaxoSmithKline (in partnership with Sanofi Pasteur) look to stage three trials of their Covid-19 vaccine, the company has not yet released a vaccine to market. The global rollout of Covid-19 vaccines (by competitors) looks to have disrupted the course of other vaccine programmes in key markets such as the US and the UK for GSK. Revenue for second quarter (Q2) 2021 is expected to be bolstered by sales of newer drugs in the respiratory and HIV segments, with a partial offset from older drugs which are finding increased competition through generic offerings. In terms of the upcoming results, a mean of analyst estimates compiled by Refinitiv data arrive at the following: Revenue $10.433 billion (+10.27%) year on year (YoY) Earnings before interest tax depreciation amortisation (EBITDA) $2.855 billion (-8.91% YoY) Earnings per share (EPS) $0.51 (+10.87% YoY) How to trade the GlaxoSmithKline results   Source: Refinitiv   A Refinitiv poll of analyst ratings arrive have a long term consensus rating of ‘buy’ for GlaxoSmithKline with a target price $47.87. GlaxoSmithKline (ADR) share price: technical analysis   Source: IG The share price of GlaxoSmithKline continues to trade in an uptrend which has been in place since the beginning of March 2021. The price has however started to correct from near term highs. The correction sees the price now testing support at the 38.85 level. Traders looking for long entry might prefer to see a bullish price reversal around current levels accompanied by a sharper move out of oversold territory by the Stochastic oscillator. In this scenario, the recent high at 40.55 would become the initial resistance target, while a close below 38.35 could be used as a stop loss consideration for the trade. However should a bullish price reversal not manifest and we see the price move to close below both the 38.85 and 38.35 support levels, this could instead be a suggestion that the uptrend has failed and perhaps a new downtrend for the share price is forming. In Summary GSK reports Q2 2021 results on the 28 July Q2 revenue of $10.433 billion (+10.27% YoY) is expected Q2 EBITDA of $2.855 billion (-8.91% YoY) are expected EPS $0.51 (+10.87% YoY) in the Q2 are expected The average long term broker rating for GSK is a ‘buy’ The share price of GSK is testing support as it finds itself in a short-term correction of a longer-term uptrend
    • Alibaba continues to enjoy strong revenue and customer growth, but the decline in its stock price reflects a bleaker outlook thanks to the actions of the Chinese government. Source: Bloomberg   Shares Alibaba Group China Investor IPO Price  Chris Beauchamp | Chief Market Analyst, London | Publication date: Tuesday 27 July 2021    When is Alibaba’s earnings date? Alibaba reports earnings on 3 August, covering its fiscal first quarter (Q1). Alibaba earnings – what to expect Alibaba is expected to report revenue of $32 billion, with earnings per share of $2.24. Alibaba continues to enjoy excellent growth, achieving one billion customers in the 2021 financial year (FY2021), with the vast majority of these based in China. Profit margins and revenues have risen at a steady pace in every year since 2013, at 10% and 23% respectively. However, for Chinese tech shares such as Alibaba, the main concern is no longer business performance, but the attitude of the Chinese government instead. The cancellation of the Ant Financial initial public offering (IPO) and the current clampdown on tutoring stocks points towards a much more restrictive approach to the private sector. As many could have predicted, the culture clash between free market capitalism and the controlling instincts of the Chinese Communist Party has begun anew, with the Party determined to rein in the perceived excesses of the free market. This is a situation unfamiliar to many investors, unused to the impact of government interference on most companies except in relatively isolated circumstances, and accounts for the underperformance of Chinese shares, with Alibaba no exception. Find out more on how to buy, sell, and short Alibaba shares Alibaba broker ratings A total of 17 analysts currently rate Alibaba as a ‘strong buy’, with 30 more at ‘buy’. Three analysts have a ‘hold’ rating, and only one ‘sell’. Alibaba stock – technical analysis The direction in Alibaba stock is clear for the time being. Rallies have been regularly sold, with the latest bounce in late June running into the 100-day simple moving average (SMA), currently 22,225. With the macro outlook so unfavourable the stock continues to reflect investor caution, so it looks like further declines are on the cards as the price targets 18,000 and lower.   Source: ProRealTime A solid business, but outlook continues to darken Alibaba has plenty to commend it from a fundamental perspective, but with Beijing adopting an activist position the stock continues to decline. Investors might argue that this means Alibaba is becoming a bargain, but traders will want to see a turnaround in the price, which is unlikely to happen unless the Chinese government reduces its interventions.
    • EUR/USD, GBP/USD and NZD/USD weaken from Fibonacci resistance EUR/USD, GBP/USD and NZD/USD turn lower after posting a deep 76.4% Fibonacci retracement.   Forex NZD/USD EUR/USD GBP/USD Pound sterling Euro    Joshua Mahony | Senior Market Analyst, London | Publication date: Tuesday 27 July 2021  EUR/USD turning lower from latest retracement EUR/USD has managed to post yet another 76.4% Fibonacci retracement, with the pair heading lower once again. This highlights how the trend seen over the course of the past two months remains worth following. While the trend is very shallow in nature, that does bring a higher likeliness of a deep retracement. As such, a bearish outlook holds from here, with a push up through the prior swing-high of $1.183 required to negate that downside bias. Source: ProRealTime GBP/USD turning lower after 76.4% retracement GBP/USD has started to lose ground in early trade today, following the rally into the 76.4% Fibonacci resistance level at $1.383. With a wider bearish trend playing out over recent months, there is a good chance we see further downside from here. A rise up through the $1.391 level would be required to negate that outlook. Source: ProRealTime NZD/USD slumps after deep pullback NZD/USD has similarly turned lower after a 76.4% Fibonacci retracement yesterday. The wider downtrend points towards such a move coming into play, with a rise through $0.7045 required to negate that bearish outlook. Until then, further weakness looks likely from here. Source: ProRealTime
  • Create New...